查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040418

美國疫苗市場規模、佔有率和趨勢分析報告：按適應症、類型、支付方、年齡層、目標人群、使用/劑量模式、收入和細分市場預測（2026-2033 年）

U.S. Vaccines Market Size, Share & Trends Analysis Report By Indication, By Type, By Payer Type, By Age Group, By Use Populations, By Usage/Administration Pattern, By Sales, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國疫苗市場概況

據估計，美國疫苗市場在 2025 年的價值為 260 億美元，預計到 2033 年將達到 401.9 億美元，2026 年至 2033 年的複合年成長率為 5.40%。

美國疫苗市場的發展動力源自於疫苗技術的快速進步與平台創新。

mRNA、重組和載體技術的應用正在加速開發更有效、更具標靶性的疫苗，以應對多種疾病。製劑、佐劑和遞送系統的持續改進正在增強免疫反應和整體產品性能。對精準免疫的日益重視正在推動針對特定族群和疾病風險的客製化疫苗的研發。

製造技術的進步提高了規模化生產能力，縮短了生產前置作業時間，並確保了產品品質的穩定性。強大的研發管線和更短的開發週期使得應對新出現的健康威脅能夠迅速回應。這些因素增強了創新能力，並支持了美國疫苗市場的持續成長。例如，2026年1月，美國衛生與公共服務部宣布，根據2025年12月5日發布的總統備忘錄，該部門已接受美國疾病管制與預防中心（CDC）關於修訂美國兒童免疫接種計畫的建議。一項針對20個已開發國家免疫接種檢驗的科學評估發現，到2024年，美國將提供18種疾病的預防措施，而丹麥僅提供10種疾病的預防措施。該分析還表明，美國建議的兒童疫苗種類更多，接種劑量是某些歐洲國家的兩倍多，同時還保持了三種免疫接種類別由保險全額覆蓋，無需個人自付費用。

在美國，成人疫苗需求的成長是推動市場擴張的關鍵因素。隨著人口老化，感染疾病的盛行率不斷上升，導致疫苗接種的需求範圍擴大，涵蓋更多適應症和風險族群。公眾健康意識的提高促進了成人（包括慢性病患者）的常規免疫接種。透過藥局、診所和職場計畫擴大疫苗接種管道，提高了接種的便利性和接種率。呼吸道感染疾病（例如流感和呼吸道融合細胞病毒(RSV)）發生率的上升，推動了各地對季節性疫苗的需求。預期壽命的延長凸顯了兒童期後繼續接種疫苗的重要性。例如，美國疾病管制與預防中心 (CDC) 於 2025 年 10 月更新了 19 歲及以上人口的成人免疫接種計劃，涵蓋四個年齡層：19-26 歲、27-49 歲、50-64 歲和 65 歲及以上。此免疫接種計畫建議進行基礎免疫接種，包括一劑或多劑新冠疫苗、每年一次流感疫苗、三劑破傷風、白喉和百日咳聯合疫苗（Tdap），之後每10年接種一次加強針，每次懷孕期間接種一次加強針，50-74歲和75歲及以上成人接種一劑呼吸道融合細胞病毒（RSV）疫苗合胞病毒（RSV）疫苗。同時，建議59歲以下族群接種B型肝炎疫苗。這項系統性的免疫接種計畫增強了成人疫苗需求的永續性和長期收入的穩定性。

疫苗組合的擴展和跨疾病免疫策略的演進進一步推動了這個市場的發展。聯合疫苗的研發提高了接種的便利性，減少了所需劑量，並提高了病患的依從性。疫苗配方的定期更新正在應對新出現的變異株和人群中流行病學模式的變化。拓展到包括腫瘤學和個人化疫苗在內的新治療領域，正在創造更多的成長機會。改進的供應鏈系統支持了醫療機構中高效的疫苗分發、儲存和交付。研究網路之間合作的加強正在加速創新和臨床開發。例如，2026年1月，《健康政策觀察》報道稱，美國衛生部門大幅修訂了兒童免疫接種計劃，將常規免疫接種涵蓋的疾病數量從17種減少到11種，並取消了六種疫苗的普遍接種建議，包括輪狀病毒、流感疫苗、腦膜炎疫苗、病菌感染疫苗、乙型肝炎疫苗和呼吸道融合細胞病毒（RSV）疫苗。此次修訂也將人類乳突病毒 (HPV) 疫苗的接種要求從兩劑減少到一劑。此前，美國於 2025 年 12 月 5 日發布了相關指南，呼籲與其他國家（如丹麥、日本、澳洲、加拿大和英國）進行比較研究（這些國家分別建議接種針對 10 種、14 種和 15 種疾病的疫苗）。先前的指南估計，美國兒童在 18 年內大約可以接種 35 至 36 劑疫苗，但僅呼吸道融合細胞病毒每年就導致約 8 萬名兒童住院，因此疫苗接種計畫的調整凸顯了其對公共衛生和市場的重要影響。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：美國疫苗市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：美國疫苗市場－市場：進入與監管狀況

  • 美國疫苗法律規範：CBER 與 CDER 的比較
  • 美國疫苗核准流程（IND → BLA → GMP → 批間一致性測試）
  • 有條件核准、加速核准程序以及 IV 期試驗要求
  • 進入美國疫苗市場的臨床試驗策略
  • 進入美國疫苗市場的關鍵考量因素
  • 分析師觀點與KOL洞察

第5章：美國疫苗市場：產品用途與建議

  • 免疫實踐諮詢委員會（ACIP）的作用
  • 醫療服務提供者、保險公司和各州對ACIP建議的採納情況
  • 美國疫苗市場的報銷趨勢
  • 美國強制免疫接種要求
  • 產品使用政策對市場的影響
  • 分析師觀點和KOL洞察

第6章 美國疫苗市場：- 藥物安全監測與法律體制

  • 上市後安全監測
  • 法律方面的考量
  • 國家疫苗傷害賠償制度的作用
  • 分析師觀點和KOL洞察

第7章：美國疫苗市場：依適應症分類的業務分析

  • 按適應症分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 病毒疫苗
  • 細菌疫苗
  • 癌症疫苗
  • 過敏疫苗
  • 其他

第8章：美國疫苗市場：按類型分類的業務分析

  • 按產品類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 次單位疫苗
  • 去活化疫苗
  • 活病毒疫苗
  • 藥效疫苗
  • 病毒載體疫苗

第9章：美國疫苗市場：按支付方分類的業務分析

  • 按支付實體分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按支付方分類，2021-2033 年
  • 公共保險機構
  • 私人保險公司
  • 自費/自籌資金
  • 其他

第10章：美國疫苗市場：按年齡層別分類的業務分析

  • 按年齡層別分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按年齡層別分類，2021-2033 年
  • 兒童（0-17歲）
  • 成年人（18-64歲）
  • 老年人（65歲以上）

第11章：美國疫苗市場：按目標族群分類的商業分析

  • 按目標群體分類的市場佔有率，2025 年和 2033 年
  • 按目標群體分類的市場規模、預測和趨勢分析（2025 年和 2033 年）
  • 職場
  • 學校
  • 旅行者
  • 軍事和特殊職業
  • 其他

第12章：美國疫苗市場：按使用和劑量模式分類的業務分析

  • 按使用/劑量模式分類的市場佔有率，2025 年和 2033 年
  • 按應用和管理模式分類的市場規模、預測和趨勢分析（2025 年和 2033 年）
  • 季節性疫苗
  • 全年疫苗
  • 其他

第13章：美國疫苗市場：銷售業務分析

  • 2025年及2033年的銷售佔有率
  • 市場規模、預測與趨勢分析（按銷售收入計算，2021-2033 年）
  • 基於競標
  • 直接向醫療機構銷售

第14章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Pfizer
    • GSK
    • Merck & Co.（MSD）
    • Sanofi
    • Moderna
    • Novavax
    • CSL Limited
    • AstraZeneca
    • Serum Institute of India
Product Code: GVR-4-68040-893-7

U.S. Vaccines Market Summary

The U.S. vaccines market size was estimated at USD 26.00 billion in 2025 and is projected to reach USD 40.19 billion by 2033, growing at a CAGR of 5.40% from 2026 to 2033. The U.S. vaccines market is driven by rapid advancements in vaccine technologies and platform innovation.

The adoption of mRNA, recombinant, and vector-based approaches is accelerating the development of more effective and targeted vaccines across multiple disease areas. Continuous improvements in formulation, adjuvants, and delivery systems are enhancing immune response and overall product performance. Increasing focus on precision-based immunization is supporting the development of vaccines tailored to specific populations and disease risks.

Advancements in manufacturing technologies are improving scalability, reducing production timelines, and ensuring consistent quality. Strong research pipelines and faster development cycles are enabling quicker responses to emerging health threats. These factors are strengthening innovation capabilities and supporting sustained growth across the U.S. vaccines market. For instance, in January 2026, the U.S. Department of Health and Human Services announced that the Centers for Disease Control and Prevention had accepted recommendations to revise the U.S. childhood immunization schedule following a Presidential Memorandum issued on December 5, 2025. The scientific assessment reviewed immunization practices across 20 peer-developed nations and found that, in 2024, the United States provided protection against 18 diseases, compared to Denmark, which immunized children against 10 diseases. The analysis also indicated that the U.S. recommended more childhood vaccines and more than twice as many doses as some European countries, while retaining three fully insured immunization categories without cost sharing.

Growing demand for adult immunization is a key factor supporting market expansion in the United States. Rising prevalence of infectious diseases among aging populations is increasing the need for vaccines across multiple indications and risk groups. Higher awareness of preventive healthcare is encouraging routine vaccination among adults, including those with chronic conditions. Expansion of vaccination access through pharmacies, clinics, and workplace programs is improving convenience and uptake. Increasing incidence of respiratory infections such as influenza and respiratory syncytial virus is driving seasonal vaccine demand across regions. A longer life expectancy reinforces the importance of ongoing immunization beyond early life stages. For instance, in October 2025, the Centers for Disease Control and Prevention released an updated adult immunization schedule for individuals aged 19 years and older, covering four age cohorts, 1926 years, 2749 years, 5064 years, and 65 years and above. The schedule recommended one or more doses of the COVID-19 vaccine, one influenza dose annually, a three-dose tetanus, diphtheria, and pertussis primary series followed by one booster every 10 years and one additional dose during each pregnancy, as well as one respiratory syncytial virus vaccine dose for adults aged 5074 years and those aged 75 years or older, while hepatitis B vaccination was recommended through 59 years of age. These structured dosing intervals reinforced sustained adult vaccine demand and long-term revenue stability.

The market is further driven by portfolio expansion and evolving vaccination strategies across disease areas. Increasing development of combination vaccines is improving convenience, reducing the number of doses, and enhancing patient compliance. Regular updates in vaccine formulations are addressing emerging variants and changing epidemiological patterns across populations. Expansion into new therapeutic areas, including oncology and personalized vaccines, is creating additional growth opportunities. Improvements in supply chain systems are supporting efficient distribution, storage, and availability across healthcare settings. Increased collaboration across research networks is accelerating innovation and clinical development. For instance, in January 2026, Health Policy Watch reported that U.S. health authorities implemented a major revision to the childhood immunization schedule, reducing the number of diseases covered by routine vaccination from 17 to 11 and removing universal recommendations for six vaccines, including those for rotavirus, influenza, meningococcal disease, hepatitis A, hepatitis B, and respiratory syncytial virus. The revision also reduced the human papillomavirus vaccination requirement from two doses to one and followed a December 5, 2025 directive to review national practices against peer nations such as Denmark, Japan, Australia, Canada, and the United Kingdom, which recommended vaccines for 10, 14, and 15 diseases, respectively. Previous guidance indicated that children in the United States could receive approximately 35 to 36 doses across 18 years, while respiratory syncytial virus alone accounted for about 80,000 pediatric hospitalizations annually, highlighting the significant public health and market implications of schedule changes.

U.S. Vaccines Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. vaccines market report based on indication, type, payer type, age group, use populations, usage/administration pattern, and sales:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Viral Vaccines
    • Hepatitis
    • Influenza
    • HPV
    • MMR
    • Rotavirus
    • Herpes Zoster
    • Japanese Encephalitis
    • RSV
    • Others
  • Bacterial Vaccines
    • Meningococcal Diseases
    • Pneumococcal Diseases
    • DPT
    • Others
  • Cancer Vaccines
  • Allergy Vaccines
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Subunit Vaccines
    • Recombinant Vaccines
    • Conjugate Vaccines
    • Toxoid Vaccines
  • Inactivated
  • Live Attenuated
  • mRNA Vaccines
  • Viral Vector Vaccines
  • Payer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Public Payer
    • Medicare
    • Medicaid
    • Federal Programs
  • Private Payers
    • Commercial Insurance Plans
    • Workplace Programs
  • Out-of-Pocket / Self-Pay
  • Others
  • Age Group Outlook (Revenue, USD Million, 2021 - 2033)
  • Pediatrics (0-17 years)
  • Adults (18-64 years)
  • Elderly (65+ years)
  • Use Populations Outlook (Revenue, USD Million, 2021 - 2033)
  • Workplace
  • Schools
  • Travelers
  • Military & Special Occupations
  • Others
  • Usage/Administration Pattern Outlook (Revenue, USD Million, 2021 - 2033)
  • Seasonal Vaccines
  • Year-Round Vaccines
  • Others
  • Sales Outlook (Revenue, USD Million, 2021 - 2033)
  • Tender-Based
  • Direct Sales to Providers

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Type
    • 1.2.3. Payer Type
    • 1.2.4. Age Group
    • 1.2.5. Use Populations
    • 1.2.6. Usage/Administration Pattern
    • 1.2.7. Sales
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Vaccine Market - Market Entry & Regulatory Landscape

  • 4.1. Regulatory Framework for Vaccines in the U.S.: CBER vs. CDER
  • 4.2. Vaccine Approval Pathway in the U.S. (IND -> BLA -> GMP -> Lot Consistency Trials)
    • 4.2.1. Preclinical Development and IND Submission
    • 4.2.2. Clinical Development Phases
    • 4.2.3. Biologics License Application (BLA)
    • 4.2.4. GMP Compliance and Manufacturing Validation
    • 4.2.5. Lot Consistency Trials and Lot Release
  • 4.3. Conditional Approvals, Accelerated Pathways, and Phase IV Requirements
    • 4.3.1. Accelerated Approval and Priority Review
    • 4.3.2. Emergency Use Authorization (EUA)
    • 4.3.3. Phase IV Post-Marketing Requirements
    • 4.3.4. Pharmacovigilance and Safety Monitoring
  • 4.4. Clinical Trial Strategy for U.S. Vaccine Market Entry
    • 4.4.1. FDA Expectations for Vaccine Trials
    • 4.4.2. Ethnic and Demographic Representation
    • 4.4.3. State-Level Enrollment Feasibility
    • 4.4.4. Impact of U.S. Immunization Policy on Trial Design
    • 4.4.5. Market Entry Strategy
  • 4.5. Key Implications for Market Entry in the U.S. Vaccine Market
  • 4.6. Analyst Perspective & Key Opinion Leader (KOL) Insights

Chapter 5. U.S. Vaccine Market - Product Usage & Recommendations

  • 5.1. Role of the Advisory Committee on Immunization Practices (ACIP)
    • 5.1.1. ACIP Composition And Structure
    • 5.1.2. Meeting Process And Decision Framework
    • 5.1.3. Influence On Market Adoption
  • 5.2. Adoption of ACIP Recommendations Across Providers, Payers, and States
    • 5.2.1. Provider Adoption
    • 5.2.2. Payer Adoption
    • 5.2.3. State-Level Variation
    • 5.2.4. Adoption Timeline Pattern
  • 5.3. Reimbursement Dynamics in the U.S. Vaccine Market
    • 5.3.1. Public Programs
    • 5.3.2. Private Insurance Coverage
    • 5.3.3. Out-Of-Pocket Costs
  • 5.4. Mandatory Vaccination Requirements in the United States
    • 5.4.1. School Entry Requirements
    • 5.4.2. Workplace Requirements
    • 5.4.3. Vaccination Recommendations For Elderly Populations
    • 5.4.4. State-Level Policy Differences
  • 5.5. Market Impact of Product Usage Policies
  • 5.6. Analyst Perspective & Key Opinion Leader Insights
    • 5.6.1. Role Of The Advisory Committee On Immunization Practices (ACIP)
      • 5.6.1.1. Analyst Perspective
    • 5.6.2. Adoption Of ACIP Recommendations Across Providers, Payers, And States
      • 5.6.2.1. Analyst Perspective
    • 5.6.3. Reimbursement Dynamics In The U.S. Vaccine Market
      • 5.6.3.1. Analyst Perspective
    • 5.6.4. Mandatory Vaccination Requirements In The United States
      • 5.6.4.1. Analyst Perspective
    • 5.6.5. Implications For Vaccine Market Uptake

Chapter 6. U.S. Vaccine Market - Pharmacovigilance & Legal Framework

  • 6.1. Post-marketing safety monitoring
    • 6.1.1. Government Requirements
    • 6.1.2. Adverse Event Reporting
    • 6.1.3. Recall Process
    • 6.1.4. Case Study Evaluation: Historical And Recent Safety Actions
  • 6.2. Legal considerations
    • 6.2.1. Manufacturer Vs. Distributor Responsibilities
    • 6.2.2. Liability Exposure
  • 6.3. Role of the National Vaccine Injury Compensation
  • 6.4. Analyst Perspective & Key Opinion Leader Insights

Chapter 7. U.S. Vaccines Market: Indication Business Analysis

  • 7.1. Indication Market Share, 2025 & 2033
  • 7.2. Indication Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 7.4. Viral Vaccines
    • 7.4.1. Viral Vaccines Market, 2021 - 2033 (USD Million)
    • 7.4.2. Hepatitis
      • 7.4.2.1. Hepatitis Market, 2021 - 2033 (USD Million)
    • 7.4.3. Influenza
      • 7.4.3.1. Influenza Market, 2021 - 2033 (USD Million)
    • 7.4.4. HPV
      • 7.4.4.1. HPV Market, 2021 - 2033 (USD Million)
    • 7.4.5. MMR
      • 7.4.5.1. MMR Market, 2021 - 2033 (USD Million)
    • 7.4.6. Rotavirus
      • 7.4.6.1. Rotavirus Market, 2021 - 2033 (USD Million)
    • 7.4.7. Herpes Zoster
      • 7.4.7.1. Herpes Zoster Market, 2021 - 2033 (USD Million)
    • 7.4.8. Japanese Encephalitis
      • 7.4.8.1. Japanese Encephalitis Market, 2021 - 2033 (USD Million)
    • 7.4.9. RSV
      • 7.4.9.1. RSV Market, 2021 - 2033 (USD Million)
    • 7.4.10. Others
      • 7.4.10.1. Others Market, 2021 - 2033 (USD Million)
  • 7.5. Bacterial Vaccines
    • 7.5.1. Bacterial Vaccines Market, 2021 - 2033 (USD Million)
    • 7.5.2. Meningococcal Diseases
      • 7.5.2.1. Meningococcal Diseases Market, 2021 - 2033 (USD Million)
    • 7.5.3. Pneumococcal Diseases
      • 7.5.3.1. Pneumococcal Diseases Market, 2021 - 2033 (USD Million)
    • 7.5.4. DPT
      • 7.5.4.1. DPT Market, 2021 - 2033 (USD Million)
    • 7.5.5. Others
      • 7.5.5.1. Others Market, 2021 - 2033 (USD Million)
  • 7.6. Cancer Vaccines
    • 7.6.1. Cancer Vaccines Market, 2021 - 2033 (USD Million)
  • 7.7. Allergy Vaccines
    • 7.7.1. Allergy Vaccines Market, 2021 - 2033 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. U.S. Vaccines Market: Type Business Analysis

  • 8.1. Type Market Share, 2025 & 2033
  • 8.2. Type Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 8.4. Subunit Vaccines
    • 8.4.1. Subunit Vaccines Market, 2021 - 2033 (USD Million)
    • 8.4.2. Recombinant Vaccines
      • 8.4.2.1. Recombinant Vaccines Market, 2021 - 2033 (USD Million)
    • 8.4.3. Conjugate Vaccines
      • 8.4.3.1. Conjugate Vaccines Market, 2021 - 2033 (USD Million)
    • 8.4.4. Toxoid Vaccines
      • 8.4.4.1. Toxoid Vaccines Market, 2021 - 2033 (USD Million)
  • 8.5. Inactivated
    • 8.5.1. Inactivated Market, 2021 - 2033 (USD Million)
  • 8.6. Live Attenuated
    • 8.6.1. Live Attenuated Market, 2021 - 2033 (USD Million)
  • 8.7. mRNA Vaccines
    • 8.7.1. mRNA Vaccines Market, 2021 - 2033 (USD Million)
  • 8.8. Viral Vector Vaccines
    • 8.8.1. Viral Vector Vaccines Market, 2021 - 2033 (USD Million)

Chapter 9. U.S. Vaccines Market: Payer Type Business Analysis

  • 9.1. Payer Type Market Share, 2025 & 2033
  • 9.2. Payer Type Segment Dashboard
  • 9.3. Market Size & Forecasts and Trend Analysis, by Payer type, 2021 to 2033 (USD Million)
  • 9.4. Public Payer
    • 9.4.1. Public Payer Market, 2021 - 2033 (USD Million)
    • 9.4.2. Medicare
      • 9.4.2.1. Medicare Market, 2021 - 2033 (USD Million)
    • 9.4.3. Medicaid
      • 9.4.3.1. Medicaid Market, 2021 - 2033 (USD Million)
    • 9.4.4. Federal Programs
      • 9.4.4.1. Federal Programs Market, 2021 - 2033 (USD Million)
  • 9.5. Private Payers
    • 9.5.1. Private Payers Market, 2021 - 2033 (USD Million)
    • 9.5.2. Commercial Insurance Plans
      • 9.5.2.1. Commercial Insurance Plans Market, 2021 - 2033 (USD Million)
    • 9.5.3. Workplace Programs
      • 9.5.3.1. Workplace Programs Market, 2021 - 2033 (USD Million)
  • 9.6. Out-of-Pocket / Self-Pay
    • 9.6.1. Out-of-Pocket / Self-Pay Market, 2021 - 2033 (USD Million)
  • 9.7. Others
    • 9.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 10. U.S. Vaccines Market: Age Group Business Analysis

  • 10.1. Age Group Market Share, 2025 & 2033
  • 10.2. Age Group Segment Dashboard
  • 10.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
  • 10.4. Pediatrics (0-17 years)
    • 10.4.1. Pediatrics (0-17 years) Market, 2021 - 2033 (USD Million)
  • 10.5. Adults (18-64 years)
    • 10.5.1. Adults (18-64 years) Market, 2021 - 2033 (USD Million)
  • 10.6. Elderly (65+ years)
    • 10.6.1. Elderly (65+ years) Market, 2021 - 2033 (USD Million)

Chapter 11. U.S. Vaccines Market: Use Populations Business Analysis

  • 11.1. Use Populations Market Share, 2025 & 2033
  • 11.2. Use Populations Segment Dashboard
  • 11.3. Market Size & Forecasts and Trend Analysis, by Use Populations, 2021 to 2033 (USD Million)
  • 11.4. Workplace
    • 11.4.1. Workplace Market, 2021 - 2033 (USD Million)
  • 11.5. Schools
    • 11.5.1. Schools Market, 2021 - 2033 (USD Million)
  • 11.6. Travelers
    • 11.6.1. Travelers Market, 2021 - 2033 (USD Million)
  • 11.7. Military & Special Occupations
    • 11.7.1. Military & Special Occupations Market, 2021 - 2033 (USD Million)
  • 11.8. Others
    • 11.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 12. U.S. Vaccines Market: Usage/Administration Pattern Business Analysis

  • 12.1. Usage/Administration Pattern Market Share, 2025 & 2033
  • 12.2. Usage/Administration Pattern Segment Dashboard
  • 12.3. Market Size & Forecasts and Trend Analysis, by Usage/Administration Pattern, 2021 to 2033 (USD Million)
  • 12.4. Seasonal Vaccines
    • 12.4.1. Seasonal Vaccines Market, 2021 - 2033 (USD Million)
  • 12.5. Year-Round Vaccines
    • 12.5.1. Year-Round Vaccines Market, 2021 - 2033 (USD Million)
  • 12.6. Others
    • 12.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 13. U.S. Vaccines Market: Sales Business Analysis

  • 13.1. Sales Market Share, 2025 & 2033
  • 13.2. Sales Segment Dashboard
  • 13.3. Market Size & Forecasts and Trend Analysis, by Sales, 2021 to 2033 (USD Million)
  • 13.4. Tender-Based
    • 13.4.1. Tender-Based Market, 2021 - 2033 (USD Million)
  • 13.5. Direct Sales to Providers
    • 13.5.1. Direct Sales to Providers Market, 2021 - 2033 (USD Million)

Chapter 14. Competitive Landscape

  • 14.1. Participant Overview
  • 14.2. Company Market Position Analysis
  • 14.3. Company Categorization
  • 14.4. Strategy Mapping
  • 14.5. Company Profiles/Listing
    • 14.5.1. Pfizer
      • 14.5.1.1. Overview
      • 14.5.1.2. Financial Performance
      • 14.5.1.3. Product Benchmarking
      • 14.5.1.4. Strategic Initiatives
    • 14.5.2. GSK
      • 14.5.2.1. Overview
      • 14.5.2.2. Financial Performance
      • 14.5.2.3. Product Benchmarking
      • 14.5.2.4. Strategic Initiatives
    • 14.5.3. Merck & Co. (MSD)
      • 14.5.3.1. Overview
      • 14.5.3.2. Financial Performance
      • 14.5.3.3. Product Benchmarking
      • 14.5.3.4. Strategic Initiatives
    • 14.5.4. Sanofi
      • 14.5.4.1. Overview
      • 14.5.4.2. Financial Performance
      • 14.5.4.3. Product Benchmarking
      • 14.5.4.4. Strategic Initiatives
    • 14.5.5. Moderna
      • 14.5.5.1. Overview
      • 14.5.5.2. Financial Performance
      • 14.5.5.3. Product Benchmarking
      • 14.5.5.4. Strategic Initiatives
    • 14.5.6. Novavax
      • 14.5.6.1. Overview
      • 14.5.6.2. Financial Performance
      • 14.5.6.3. Product Benchmarking
      • 14.5.6.4. Strategic Initiatives
    • 14.5.7. CSL Limited
      • 14.5.7.1. Overview
      • 14.5.7.2. Financial Performance
      • 14.5.7.3. Product Benchmarking
      • 14.5.7.4. Strategic Initiatives
    • 14.5.8. AstraZeneca
      • 14.5.8.1. Overview
      • 14.5.8.2. Financial Performance
      • 14.5.8.3. Product Benchmarking
      • 14.5.8.4. Strategic Initiatives
    • 14.5.9. Serum Institute of India
      • 14.5.9.1. Overview
      • 14.5.9.2. Financial Performance
      • 14.5.9.3. Product Benchmarking
      • 14.5.9.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. vaccines market, by indication, 2021 - 2033 (USD Million)
  • Table 4. U.S. vaccines market, by type, 2021 - 2033 (USD Million)
  • Table 5. U.S. vaccines market, by payer type, 2021 - 2033 (USD Million)
  • Table 6. U.S. vaccines market, by age group, 2021 - 2033 (USD Million)
  • Table 7. U.S. vaccines market, by use populations, 2021 - 2033 (USD Million)
  • Table 8. U.S. vaccines market, by usage/administration pattern, 2021 - 2033 (USD Million)
  • Table 9. U.S. vaccines market, by sales, 2021 - 2033

List of Figures

  • Fig. 1 U.S. vaccines market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 U.S. vaccines market dynamics
  • Fig. 11 U.S. vaccines market: Porter's five forces analysis
  • Fig. 12 U.S. vaccines market: PESTLE analysis
  • Fig. 13 Indication market, 2021 - 2033 (USD Million)
  • Fig. 14 Viral Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 15 Hepatitis market, 2021 - 2033 (USD Million)
  • Fig. 16 Influenza market, 2021 - 2033 (USD Million)
  • Fig. 17 HPV market, 2021 - 2033 (USD Million)
  • Fig. 18 MMR market, 2021 - 2033 (USD Million)
  • Fig. 19 Rotavirus market, 2021 - 2033 (USD Million)
  • Fig. 20 Herpes Zoster market, 2021 - 2033 (USD Million)
  • Fig. 21 Japanese Encephalitis market, 2021 - 2033 (USD Million)
  • Fig. 22 RSV market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Bacterial Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 25 Meningococcal Diseases market, 2021 - 2033 (USD Million)
  • Fig. 26 Pneumococcal Diseases market, 2021 - 2033 (USD Million)
  • Fig. 27 DPT market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Cancer Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 30 Allergy Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 31 Others market, 2021 - 2033 (USD Million)
  • Fig. 32 Type market, 2021 - 2033 (USD Million)
  • Fig. 33 Subunit Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 34 Recombinant Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 35 Conjugate Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 36 Toxoid Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 37 Inactivated market, 2021 - 2033 (USD Million)
  • Fig. 38 Live Attenuated market, 2021 - 2033 (USD Million)
  • Fig. 39 mRNA Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 40 Viral Vector Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 41 Payer Type market, 2021 - 2033 (USD Million)
  • Fig. 42 Public Payer market, 2021 - 2033 (USD Million)
  • Fig. 43 Medicare market, 2021 - 2033 (USD Million)
  • Fig. 44 Medicaid market, 2021 - 2033 (USD Million)
  • Fig. 45 Federal Programs market, 2021 - 2033 (USD Million)
  • Fig. 46 Private Payers market, 2021 - 2033 (USD Million)
  • Fig. 47 Commercial Insurance Plans market, 2021 - 2033 (USD Million)
  • Fig. 48 Workplace Programs market, 2021 - 2033 (USD Million)
  • Fig. 49 Out-of-Pocket / Self-Pay market, 2021 - 2033 (USD Million)
  • Fig. 50 Others market, 2021 - 2033 (USD Million)
  • Fig. 51 Age Group market, 2021 - 2033 (USD Million)
  • Fig. 52 Pediatrics (0-17 years) market, 2021 - 2033 (USD Million)
  • Fig. 53 Adults (18-64 years) market, 2021 - 2033 (USD Million)
  • Fig. 54 Elderly (65+ years) market, 2021 - 2033 (USD Million)
  • Fig. 55 Use Populations market, 2021 - 2033 (USD Million)
  • Fig. 56 Workplace market, 2021 - 2033 (USD Million)
  • Fig. 57 Schools market, 2021 - 2033 (USD Million)
  • Fig. 58 Travelers market, 2021 - 2033 (USD Million)
  • Fig. 59 Military & Special Occupations market, 2021 - 2033 (USD Million)
  • Fig. 60 Others market, 2021 - 2033 (USD Million)
  • Fig. 61 Usage/Administration Pattern market, 2021 - 2033 (USD Million)
  • Fig. 62 Seasonal Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 63 Year-Round Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 64 Others market, 2021 - 2033 (USD Million)
  • Fig. 65 Sales market, 2021 - 2033 (USD Million)
  • Fig. 66 Tender-Based market, 2021 - 2033 (USD Million)
  • Fig. 67 Direct Sales to Providers market, 2021 - 2033 (USD Million)
  • Fig. 68 Company categorization
  • Fig. 69 Company market position analysis
  • Fig. 70 Strategic framework